Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Your practitioner will discuss your situation with you during your initial consultation, and help you to devise a suitable plan and manage your expectations
doi: 10.1177/2042018821989238 167 GaddeKMAtkinsKD
N., Do, B
The article says combination therapy is typically considered when glycemic control is inadequate on GLP-1 monotherapy, or when cost, adherence or side effects favor adding an oral DPP-4 instead of increasing the GLP-1 amount
A., Sherr A., Shirin S., et al
The review concluded that the totality of these studies does not support a causal relationship between the use of GLP-1 RAs and the occurrence of SI/B. The new removal request states, Health care professionals should be prepared to discuss with patients that FDA has found no increased risk after conducting a comprehensive review of the available data
